Federal Register / Vol. 88, No. 236 / Monday, December 11, 2023 / Notices 85895 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Theodoric Mattes at 240–627–3827, or 

theodoric.mattes@nih.gov. Licensing 

information may be obtained by 

communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852; tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Recombinant IgG Monoclonal 

Antibody-Based Detection of Taenia 

Antigen In Humans And Pigs 

Description of Technology: The pork 

tapeworm, Taenia solium, is endemic in 

most of Asia, Latin America, and SubSaharan Africa. The risk of infection is 

increased in regions where pigs are 

raised in closed proximity to humans, 

with migration from endemic regions 

being directly proportional to the 

prevalence of infection in high-income 

countries. Human infection by T. solium 

occurs following oral ingestion of eggs 

passed in human feces from an infected 

carrier. The larvae can travel anywhere 

in the human body. Neurocysticercosis 

(NCC) occurs when the larvae traverse 

the blood-brain barrier and penetrate the 

central nervous system. Diagnosis of 

NCC is typically made through 

radiological imaging studies (such as 

computed tomography or magnetic 

resonance imaging) to visualize the 

morphology, stage, and location of the 

cysts. 

Investigators at NIAID have developed 

the recombinant IgG monoclonal 

antibody known as TsG10, which can 

target T. solium circulating antigens. An 

expression vector to produce TsG10 is 

available for expression in mammalian 

cell lines. The resulting construct allows 

for a scalable, repeatable, and broadly 

accessible production of monoclonal 

antibodies for both human and 

veterinary use. The TsG10 monoclonal 

antibodies are adaptable for plate-based 

diagnostic assays like ELISAs, to 

support a diagnosis of NCC. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Plate-based diagnostic immunoassays, 

both human and veterinary, for the 

detection of T. solium circulating 

antigen 

• Production of TsG10 recombinant 

monoclonal antibodies 

Competitive Advantages: 

• Detection of active T. solium infection 

• Scalable and repeatable production of 

a monoclonal antibody targeting T. 

solium 

• Materials available for development 

or licensing 

Development Stage: 

• Research Material 

Inventors: Drs. Thomas B. Nutman, 

Elise O’Connell, Theodore E. Nash, 

Siddhartha Mahanty, Hector Garcia, 

Adriana Paredes, all of NIAID 

Intellectual Property: HHS Reference 

No. E–043–2022–0 

Licensing Contact: To license this 

technology, please contact Theodoric 

Mattes at 240–627–3827, or 

theodoric.mattes@nih.gov., and 

reference E–043–2022–0. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. For 

collaboration opportunities, please 

contact Theodoric Mattes at 240–627– 

3827, or theodoric.mattes@nih.gov. 

Dated: December 5, 2023. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2023–27114 Filed 12–8–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Brian Bailey, Ph.D.; 240–669–5128 or 

301–201–9217; bbailey@mail.nih.gov. 

Licensing information may be obtained 

by communicating with the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852: tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Enhanced Immune Response With 

Stabilized Norovirus VLPs: A NextGeneration Vaccine Approach 

Description of Technology: This 

technology includes a novel 

advancement in developing vaccines 

targeting norovirus, tailored specifically 

for a more robust and effective response. 

It centers around an improved version 

of Virus-Like Particles (VLPs) uniquely 

engineered for greater stability and 

efficacy. These enhanced VLPs are 

designed to remain intact even when 

faced with the body’s immune 

responses, overcoming a key limitation 

of previous vaccine designs. This 

stability is crucial in ensuring the 

vaccine’s effectiveness, particularly in 

individuals with more robust immune 

systems who have shown limited 

response to traditional vaccines. 

Additionally, the modified VLPs are 

likely more resistant to degradation, 

making them a more reliable and 

durable solution in vaccination 

campaigns. This innovation could be a 

significant step in offering a more 

effective vaccine option for widespread 

use. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Enhanced Norovirus Vaccination: 

Specially designed to improve the 

effectiveness of vaccines against 

norovirus, particularly in individuals 

with previously low response rates to 

traditional vaccines. 

• Broad-Scale Immunization 

Programs: Suitable for large-scale public 

health initiatives due to its increased 


lotter on DSK11XQN23PROD with NOTICES1
85896 Federal Register / Vol. 88, No. 236 / Monday, December 11, 2023 / Notices 

stability and durability, potentially 

reducing the frequency of booster shots. 

• Platform for Future Vaccine 

Development: The stabilization 

techniques used in this technology 

could be applied to other vaccine 

formulations, paving the way for more 

robust and effective vaccines against 

various pathogens. 

Competitive Advantages: 

• Provides enhanced stability and 

efficacy in norovirus VLP vaccines, 

ensuring effectiveness even in 

individuals with strong immune 

responses who have previously shown 

limited vaccine response. 

• Its innovative design increases the 

VLPs’ resistance to degradation, offering 

a more durable and reliable option for 

large-scale immunization programs. 

Development Stage: 

• Pre-Clinical. 

Inventors: Lisa Lindesmith, Ralph 

Baric, George Georgiou, Peter Kwong, 

Raffaello Veradi, Yaroslav Tsybovsky, 

Jason Gorman, Gwo-Yu Chuang and Li 

Ou, all of NIAID. 

Publications: Lu, Yuan et al. 

‘‘Assessing sequence plasticity of a 

virus-like nanoparticle by evolution 

toward a versatile scaffold for vaccines 

and drug delivery.’’ Proceedings of the 

National Academy of Sciences of the 

United States of America vol. 112,40 

(2015): 12360–5. DOI: 10.1073/ 

pnas.1510533112 at https://doi.org/ 

10.1073/pnas.1510533112; Porta, 

Claudine et al. ‘‘Rational engineering of 

recombinant picornavirus capsids to 

produce safe, protective vaccine 

antigen.’’ PLoS pathogens vol. 9,3 

(2013): e1003255. DOI: 10.1371/ 

journal.ppat.1003255 at https://doi.org/ 

10.1371/journal.ppat.1003255; Mateo, 

Roberto et al. ‘‘Engineering viable footand-mouth disease viruses with 

increased thermostability as a step in 

the development of improved vaccines.’’ 

Journal of virology vol. 82,24 (2008): 

12232–40. DOI: 10.1128/JVI.01553–08 at 

https://doi.org/10.1128/jvi.01553-08; 

Bertolotti-Ciarlet, Andrea et al. 

‘‘Structural requirements for the 

assembly of Norwalk virus-like 

particles.’’ Journal of virology vol. 76,8 

(2002): 4044–55. DOI: 10.1128/ 

jvi.76.8.4044–4055.2002 at https://

doi.org/10.1128/jvi.76.8.4044- 

4055.2002; Prasad, B V et al. ‘‘X-ray 

crystallographic structure of the 

Norwalk virus capsid.’’ Science (New 

York, N.Y.) vol. 286,5438 (1999): 287– 

90. DOI: 10.1126/science.286.5438.287 

at https://doi.org/10.1126/ 

science.286.5438.287. 

Intellectual Property: HHS Reference 

No. E–178–2019–0; U.S. Provisional 

Patent Application No. 63/091,824, filed 

on October 14, 2020; PCT Patent 

Application No. PCT/US2021/55018, 

filed October 14, 2021; U.S. National 

Stage patent application, U.S. 18/ 

031,602, filed April 12, 2023. 

Licensing Contact: To license this 

technology, please contact Brian Bailey, 

Ph.D.; 240–669–5128 or 301–201–9217; 

bbailey@mail.nih.gov, and reference E– 

178–2019. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize this technology. For 

collaboration opportunities, please 

contact Brian Bailey, Ph.D.; 240–669– 

5128 or 301–201–9217; bbailey@

mail.nih.gov. 

Dated: December 5, 2023. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2023–27112 Filed 12–8–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Cancer 

Institute Special Emphasis, Panel SEP– 

1: NCI Clinical and Translational Cancer 

Research, February 7, 2024, 9:00 a.m. to 

February 7, 2024, 5:00 p.m., National 

Cancer Institute Shady Grove, 9609 

Medical Center Drive, Room 7W108, 

Rockville, Maryland, 20850 which was 

published in the Federal Register on 

November 17, 2023, FR Doc. 2023– 

25490, 88 FR 80322. 

This notice is being amended to 

change the meeting date from February 

7, 2024, to February 20, 2024. The 

meeting location and time will stay the 

same. The meeting is closed to the 

public. 

Dated: December 5, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–27069 Filed 12–8–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID: FEMA–2023–0033; OMB No. 

1660–NW171] 

Agency Information Collection 

Activities: Proposed Collection, 

Comment Request; Generic Clearance 

for FEMA’s Collection of Feedback on 

Customer Satisfaction and Disaster 

Recovery 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: 60-Day notice of new collection 

and request for comments. 

SUMMARY: The Federal Emergency 

Management Agency (FEMA), as part of 

its continuing effort to reduce 

paperwork and respondent burden, 

invites the general public to take this 

opportunity to comment on a new 

information collection. In accordance 

with the requirements of the Paperwork 

Reduction Act of 1995, this notice seeks 

comments concerning a generic 

clearance to collect feedback from 

applicants on service delivery and their 

subsequent disaster recovery. 

DATES: Comments must be submitted on 

or before February 9, 2024. 

ADDRESSES: To avoid duplicate 

submissions to the docket, please 

submit comments at 

www.regulations.gov under Docket ID 

FEMA–2023–0033. Follow the 

instructions for submitting comments. 

All submissions received must 

include the agency name and Docket ID. 

Regardless of the method used to 

submitting comments or material, all 

submissions will be posted, without 

change, to the Federal eRulemaking 

Portal at http://www.regulations.gov, 

and will include any personal 

information you provide. Therefore, 

submitting this information makes it 

public. You may wisht to read the 

Privacy and Security Notice that is 

available via a link on the homepage of 

www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Kristin Brooks, Statistician, FEMA’s 

Recovery Reporting and Analytics 

Division, Customer Survey and Analysis 

Section, at (202) 826–6291 or 

Kristin.Brooks@fema.dhs.gov. You may 

contact the Information Management 

Division for copies of the proposed 

collection of information at email 

address: FEMA-Information-CollectionsManagement@fema.dhs.gov. 

SUPPLEMENTARY INFORMATION: Executive 

Order 12862, ‘‘Setting Customer Service 


lotter on DSK11XQN23PROD with NOTICES1